Detail akcie Mira Phar Rg online

Business Summary: MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Mira Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $5.5M to $26M. Higher net loss reflects General and administrative expenses increase of 10% to $3.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.34 to -$1.38.